Lava Therapeutics Nv (LVTX)

Apr 16, 2025

LAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise Agency - Nasdaq

Apr 16, 2025

Apr 16, 2025

Lava Therapeutics Granted Full Waiver For RVO Payment Obligation - marketscreener.com

Apr 16, 2025

Apr 16, 2025

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - GlobeNewswire

Apr 16, 2025

Apr 16, 2025

LAVA Therapeutics Strengthens Balance Sheet: Secures Complete Waiver of $5.1M Debt - Stock Titan

Apr 16, 2025

Apr 06, 2025

Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues - simplywall.st

Apr 06, 2025

Apr 01, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut - Investing.com India

Apr 01, 2025

Apr 01, 2025

LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright - Defense World

Apr 01, 2025

Mar 31, 2025

Leerink cuts Lava Therapeutics stock target to $1 By Investing.com - Investing.com Canada

Mar 31, 2025

Mar 31, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Leerink cuts Lava Therapeutics stock target to $1 - Investing.com

Mar 31, 2025

Mar 31, 2025

JMP maintains LAVA Therapeutics stock Market Perform rating By Investing.com - Investing.com Australia

Mar 31, 2025

Mar 31, 2025

JMP maintains LAVA Therapeutics stock Market Perform rating - Investing.com

Mar 31, 2025

Mar 28, 2025

Lava Therapeutics Reports 2024 Financial Results - TipRanks

Mar 28, 2025

Mar 28, 2025

LAVA Therapeutics NV earnings beat by $0.16, revenue topped estimates - Investing.com Australia

Mar 28, 2025

Mar 28, 2025

LAVA Therapeutics N.V. (LVTX) reports earnings - Quartz

Mar 28, 2025

Mar 28, 2025

LAVA Therapeutics NV SEC 10-K Report - TradingView

Mar 28, 2025

Mar 28, 2025

LAVA Therapeutics NV reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025

Mar 28, 2025

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire

Mar 28, 2025

Mar 28, 2025

LAVA Therapeutics Q4 Basic EPS USD -0.14 - MarketScreener

Mar 28, 2025

Mar 28, 2025

LAVA Therapeutics Slashes Workforce 30% While Securing $12M in Big Pharma Milestone Payments - Stock Titan

Mar 28, 2025

Mar 12, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 12, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts - Investing.com

Mar 12, 2025

Feb 28, 2025

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang - Benzinga

Feb 28, 2025

Feb 27, 2025

This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga

Feb 27, 2025

Feb 25, 2025

LAVA Therapeutics Reviews Strategic Alternatives, Announces 30% Staff Cut - Nasdaq

Feb 25, 2025

Feb 25, 2025

LAVA Therapeutics Announces Restructuring Plan for 2025 - TipRanks

Feb 25, 2025

Feb 25, 2025

LAVA Announces Evaluation of Strategic Options - GlobeNewswire

Feb 25, 2025

Feb 25, 2025

Can LAVA Therapeutics Find a Buyer? Company Cuts 30% of Staff While Exploring Strategic Options - StockTitan

Feb 25, 2025

Feb 13, 2025

LVTX stock touches 52-week low at $0.88 amid market challenges - Investing.com Australia

Feb 13, 2025

Feb 12, 2025

LVTX stock touches 52-week low at $0.88 amid market challenges By Investing.com - Investing.com South Africa

Feb 12, 2025

Feb 06, 2025

LAVA Therapeutics (NASDAQ:LVTX) Stock Price Down 4.6% – Here’s What Happened - Defense World

Feb 06, 2025

Jan 27, 2025

RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR

Jan 27, 2025

Jan 10, 2025

LAVA Therapeutics begins trial for cancer treatment - Investing.com India

Jan 10, 2025

Jan 10, 2025

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire

Jan 10, 2025

Jan 10, 2025

LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 - StockTitan

Jan 10, 2025

Jan 09, 2025

LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register

Jan 09, 2025

Jan 04, 2025

LAVA Therapeutics NV Files 8-K with SEC, Transitioning to U.S. Domestic Issuer Status - Defense World

Jan 04, 2025

Dec 26, 2024

LVTX stock touches 52-week low at $0.95 amid market challenges - Investing.com

Dec 26, 2024

Dec 20, 2024

H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization By Investing.com - Investing.com South Africa

Dec 20, 2024

Dec 20, 2024

H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization - Investing.com

Dec 20, 2024

Dec 18, 2024

LAVA Therapeutics stock hits 52-week low at $0.98 - Investing.com

Dec 18, 2024